Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | MLLT1 | Q03111 | 3/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14091373 | 0.93 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091383 | 0.84 | HDAC6 (0.69) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14115824 | 0.82 | HDAC6 (0.72) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL18229530 | 0.80 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14090293 | 0.79 | HDAC6 (0.56) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091344 | 0.79 | HDAC6 (0.67) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091398 | 0.79 | HDAC6 (0.67) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091369 | 0.79 | HDAC6 (0.67) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL12833987 | 0.79 | MMP2 (0.53) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL14091354 | 0.79 | HDAC6 (0.61) | HDAC6HDAC3HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | HDAC6 541/4885HDAC3 911/4885HDAC1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.